Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Thrombosis Drugs Market

Thrombosis Drugs Market Trends

  • Report ID: GMI8685
  • Published Date: Mar 2024
  • Report Format: PDF

Thrombosis Drugs Market Trends

The market is experiencing several notable trends that are shaping its growth and development. Factors such as rising need for novel oral anticoagulants (NOACs), growing emphasis on personalized medicine, continuous technological innovations in drug delivery system, and a surging demand for combination therapies, among other factors are propelling the industry landscape.
 

  • Further, there is a growing trend towards outpatient management of thrombotic disorders, driven by factors such as cost containment, patient preference, and rapid technological advancements in home healthcare. Healthcare providers are increasingly managing thrombosis patients in outpatient settings, utilizing oral anticoagulants and self-administered injectables for long-term anticoagulation therapy. This trend supports patient-centered care, improves healthcare access, and reduces the burden on hospital resources.
     
  • Moreover, technological advancements in novel drug delivery systems are driving innovation in thrombosis drug formulations and administration routes. Long-acting formulations, transdermal patches, and implantable devices offer improved convenience, adherence, and safety compared to traditional oral or injectable therapies. Novel drug delivery technologies enhance the efficacy and tolerability of thrombosis drugs, contributing to their market acceptance and patient satisfaction.
     
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Thrombosis drugs market size was USD 31.2 billion in 2023 and is expected to register 8.2% CAGR from 2024-2032 owing to the ongoing advancements in drug development, an increase in the prevalence of thrombotic disorders, and growing geriatric population worldwide.

The anticoagulants segment recorded USD 17.8 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to increased awareness among healthcare professionals and patients about the importance of appropriate anticoagulant therapy.

North America thrombosis drugs industry recorded USD 13.4 billion in 2023 due to the rising pharmaceutical research and development, with numerous biopharmaceutical companies and academic institutions engaged in thrombosis drug discovery and clinical trials in the region.

Baxter International Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., and Sanofi, are some of the major thrombosis drugs companies worldwide.

Thrombosis Drugs Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 385
  • Countries covered: 22
  • Pages: 150
 Download Free Sample